bullish
Pessimism Overdone: Takeda Undervalued By 40% Under Modestly Enhanced Post-Deal Financial Assumption
490 Views16 Jul 2018 21:30
Takeda Pharmaceutical Co Ltd (4502 JP)’s CMP highly underappreciates potential financial transformation through its integration with Shire and the...
SUMMARY
(Sign Up to Access)Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 16-minute read)
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- Japan Pharma - Top Picks18 Dec 2018
- Takeda and Shire Shareholders Unanimously Agree to $64b Deal09 Dec 2018
- Takeda 1H FY18 (YE Mar'19) Results - First Glance31 Oct 2018
- Pessimism Overdone: Takeda Undervalued By 40% Under Modestly Enhanced Post-Deal Financial Assumption16 Jul 2018
- Takeda Acquires Shire for US$64 Billion – We Continue Our Support of the Deal08 May 2018
- No Deal Is a Big Deal for Takeda25 Apr 2018
x